Key Strategic Developments and Emerging Changes Shaping the Hereditary Angioedema Therapeutics Market Landscape

The hereditary angioedema therapeutics market is set for significant expansion in the coming years as advancements in medical treatments and global outreach continue to evolve. This sector is gaining increased attention from healthcare providers and researchers, driven by innovations that promise better management and outcomes for patients worldwide. Let's explore the current market valuation, key players, influential trends, and detailed segment breakdowns shaping this promising field.

Forecast for Market Valuation in Hereditary Angioedema Therapeutics
The hereditary angioedema therapeutics market is projected to grow swiftly, reaching a valuation of $15.84 billion by 2029. This growth is expected at a robust compound annual growth rate (CAGR) of 19.5%. Several factors contribute to this upward trajectory, including breakthroughs in targeted therapies, expanding coverage in global markets, progress in gene therapy, personalized medicine approaches, and increasing collaboration in research and development efforts. Important trends anticipated during this period involve initiatives to improve worldwide access to treatments, research focused on health economic outcomes, strategies aimed at early intervention, and specialized therapeutics for pediatric hereditary angioedema patients.

Download a free sample of the hereditary angioedema therapeutics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

Leading Companies Driving the Hereditary Angioedema Therapeutics Market
The market features a strong lineup of major players, including Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., and Pharos Pharmaceuticals Inc. A notable development occurred in February 2023 when Takeda Pharmaceutical Company, headquartered in Japan, acquired Nimbus Lakshmi Inc. from Nimbus Therapeutics LLC. This acquisition enhances Takeda's late-stage pipeline, broadening its portfolio and expected patient impact across several disease areas, supporting sustained global growth. Nimbus Lakshmi, based in the US and fully owned by Nimbus Therapeutics, is recognized for developing the Tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

Key Factors Influencing the Hereditary Angioedema Therapeutics Market's Growth
Product innovation is emerging as a major trend shaping this market's future. Companies are focusing on developing novel treatments such as ligand-conjugated (LICA) antisense medicines and cutting-edge gene therapies to maintain competitive advantage and address unmet patient needs.
An example of this trend is seen with Intellia Therapeutics, a US-based clinical-stage biotech firm, which received FDA approval in March 2023 for its Investigational New Drug (IND) application for NTLA-2002 to treat hereditary angioedema. This approval allows the company to expand its ongoing Phase 1/2 clinical trial to include a Phase 2 segment in the United States. The therapy works by permanently reducing plasma kallikrein protein activity after a single dose through inactivation of the target gene kallikrein B1 (KLKB1), thereby preventing HAE attacks. NTLA-2002 represents a promising in vivo genome editing candidate.

View the full hereditary angioedema therapeutics market report:
https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Detailed Breakdown of the Hereditary Angioedema Therapeutics Market Segments
The hereditary angioedema therapeutics market is divided into several key categories for better clarity:
1) Drug Class:
- C1 Esterase Inhibitor
- Selective Bradykinin B2 Receptor Antagonist
- Kallikrein Inhibitor
- Other Drug Classes
2) Route of Administration:
- Intravenous
- Subcutaneous
- Oral
3) Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Other Distribution Channels
4) Application:
- Prophylaxis
- On-demand
Further subcategories include:
- For C1 Esterase Inhibitor: plasma-derived and recombinant versions
- For Selective Bradykinin B2 Receptor Antagonist: icatibant
- For Kallikrein Inhibitor: ecallantide and lanadelumab
- For Other Drug Classes: emerging therapies under development

This segmentation provides a comprehensive framework for understanding the market's composition and the variety of therapeutic options available for hereditary angioedema treatment.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.